Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) IX B). Prophylaxis – regular administration therapeutic products to maintain hemostasis and prevent bleeding mainstream treatment. Addressing development scientific evidence for administrating prophylaxis goal this review. modality choice people with sev...

it seems that endometriosis plays an important role in female factor infertility but a clear causal relationship has yet to be established. this case-control study was conducted to determine and compare the frequency and severity of endometriosis in 100 infertile women and 120 fertile multi-para women as control group. descriptive statistics, student t test and chi square test were used in anal...

Case report A 54-year-old man with mild to moderate hemophilia A, obstructive sleep apnea on continuous positive airway pressure, and paroxysmal AF was referred for AF catheter ablation. Four years prior, he was evaluated for palpitations and dyspnea. AF was confirmed on ambulatory monitoring. His CHA2DS2-VASc score was 0. He was trialed on a series of antiarrhythmic medications including fleca...

human parvovirus b19, the causative agent of fifth disease in childhood, is non-enveloped dna virus and resistant to many physicochemical agents. b19 is a potential risk to hemophiliac patients receiving blood products. to determine the prevalence of the corresponding antibody in patients with hemophilia a or b or von will brand’s disease (vwbd), we tested 180 hemophilia patients aged 1-45 year...

background: hemophilia b is a bleeding disorder with a recessive x-linked inheritance pattern, in which the infected individuals have low levels of factor ix in their plasma. affected individuals may have bleeding episodes after trauma or spontaneously considering the plasma level of factor ix. in order to prevent these episodes and to control bleeding, they should use coagulation factor concen...

Background: Considering the increasing number of patients with hemophilia and infrastructure requirements for a comprehensive approach, development of a recombinant factor has become a milestone. The objective of this study was to assess the safety, efficacy and non inferiority of Safacto (Recombinant factor VIII) compared with plasma-derived factor in the treatment of hemophilia A. Methods: 10 ...

INTRODUCTION New longer-acting factor products will potentially allow for less frequent infusion in prophylactic treatment of hemophilia. However, the role of administration frequency relative to other treatment attributes in determining preferences for prophylactic hemophilia treatment regimens is not well understood. AIM To identify the relative importance of frequency of administration, ef...

BACKGROUND Although prophylaxis is a standard of care for young children in developed countries, known to reduce the severity of hemophilic arthropathy, older adults with existing arthropathy have not traditionally used prophylaxis. Recent studies have shown that adults with hemophilia A are increasingly adopting prophylaxis but the characteristics of this treatment in older adults are not well...

hemophilia b is factor ix deficiency and is inherited as x-linked recessive disorder. the subject of carrier detection in hemophilias has received new impetus in the last several years. analysis of factor ix gene polymorphisms is considered the best approach for prenatal diagnosis and hemophilia b carrier detection, if the identification of the gene mutation is possible. allele frequencies of t...